Cornel Fraefel

Prof. Dr. Cornel Fraefel

Institute of Virology, University of Zurich, 8057 Zurich, Switzerland
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2009 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
OSOkay Saydam
Okay Saydam
YSYiping Shen
Yiping Shen
TWThomas Würdinger
Thomas Würdinger
OSOzlem Senol
Ozlem Senol
EBElvan Boke
Elvan Boke
XBXandra O. Breakefield
Xandra O. Breakefield
Meningiomas, one of the most common human brain tumors, are derived from arachnoidal cells associated with brain meninges, are usually benign, and are frequently associated with neurofibromatosis type 2. Here, we define a typical human meningioma microRNA (miRNA) profile and characterize the effects of one downregulated miRNA, miR-200a, on tumor growth. Elevated levels of miR-200a inhibited meningioma cell growth in culture and in a tumor model in vivo. Upregulation of miR-200a decreased the expression of transcription factors ZEB1 and SIP1, with consequent increased expression of E-cadherin, an adhesion protein associated with cell differentiation. Downregulation of miR-200a in meningiomas and arachnoidal cells resulted in increased expression of beta-catenin and cyclin D1 involved in cell proliferation. miR-200a was found to directly target beta-catenin mRNA, thereby inhibiting its translation and blocking Wnt/beta-catenin signaling, which is frequently involved in cancer. A direct correlation was found between the downregulation of miR-200a and the upregulation of beta-catenin in human meningioma samples. Thus, miR-200a appears to act as a multifunctional tumor suppressor miRNA in meningiomas through effects on the E-cadherin and Wnt/beta-catenin signaling pathways. This reveals a previously unrecognized signaling cascade involved in meningioma tumor development and highlights a novel molecular interaction between miR-200a and Wnt signaling, thereby providing insights into novel therapies for meningiomas.

1 April 2001 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
YSYoshinaga Saeki
Yoshinaga Saeki
CFCornel Fraefel
Cornel Fraefel
TITomotsugu Ichikawa
Tomotsugu Ichikawa
XBXandra O Breakefield
Xandra O Breakefield
ECE.Antonio Chiocca
E.Antonio Chiocca
Herpes simplex virus type 1 (HSV-1) amplicons are prokaryotic plasmids containing one or more transcriptional units and two cis-acting HSV-1 sequences: a viral origin of DNA replication and a viral DNA cleavage/packaging signal. In the presence of HSV-1 “helper” functions, amplicons are replicated and packaged into HSV-1 virions. Despite recent improvements in packaging methods, stocks of amplicon vectors are still contaminated with replication-competent helper virus at a frequency of 10−4–10−6. To overcome this problem, we report that: (i) genetic modifications of HSV-1 genomes can be routinely achieved in Escherichia coli, either by homologous or site-specific recombination, (ii) a novel HSV-1 bacterial artificial chromosome (fHSVΔpacΔ27 0+), which has a deletion in the essential gene encoding ICP27 and an addition of ICP0 “stuffer” sequences to increase its size to 178 kb, supports the replication and packaging of cotransfected amplicon DNA without generating replication-competent helper virus (<1 helper virus per 108 TU amplicon vectors), and (iii) the resulting amplicon stocks have titers of up to 3–10 × 108 TU/ml after concentration. Elimination of replication-competent helper virus from HSV-1 amplicon vector stocks further improves safety in gene transfer applications.

10 December 1998 in Human Gene Therapy
Verified
Journal Article
Closed access
YSYoshinaga Saeki
Yoshinaga Saeki
TITomotsugu Ichikawa
Tomotsugu Ichikawa
ASAkane Saeki
Akane Saeki
ECE. Antonio Chiocca
E. Antonio Chiocca
KTKurt Tobler
Kurt Tobler
CFCornel Fraefel
Cornel Fraefel
Herpes simplex virus type 1 (HSV-l)-based amplicon vectors contain only ~ 1% of the 152-kb HSV-1 genome, and consequently, replication and packaging into virions depends on helper functions. These helper functions have been provided conventionally by a helper virus, usually a replication-defective mutant of HSV-1, or more recently, by a set of five cosmids that overlap and represent the genome of HSV-1 deleted for DNA cleavage/packaging signals (pac). In the absence of pac signals, potential HSV-1 genomes that are reconstituted from the cosmids via homologous recombination are not packageable. The resulting amplicon stocks are, therefore, virtually free of contaminating helper virus. To simplify this packing system, the HSV-1 genome was cloned and maintained stably as a single-copy, F plasmid-based bacterial artificial chromosome in E. coli. Such a plasmid containing the HSV-1 genome deleted for the pac signals (fHSVΔ pac) did not generate replication-competent progeny virus on transfection into mammalian cells, but rather, it was able to support the packaging of cotransfected amplicon DNA that contained a functional pac signal. The resulting amplicon vector stocks had titers of up to 107 transducing units per milliliter of culture medium and efficiently transduced neural cells in the rat brain, as well as hepatocytes in the rat. The capacity of generating infectious and replication-competent HSV-1 progeny following transfection into mammalian cells was restored after insertion of a pac signal into fHSVΔpac.

19 June 2020 in Viruses
Verified
Journal Article
Open access
PDF file
AMAnita Meier
Anita Meier
CFCornel Fraefel
Cornel Fraefel
Michael SeyffertMichael Seyffert
Michael Seyffert
The adeno-associated virus (AAV) is a small, nonpathogenic parvovirus, which depends on helper factors to replicate. Those helper factors can be provided by coinfecting helper viruses such as adenoviruses, herpesviruses, or papillomaviruses. We review the basic biology of AAV and its most-studied helper viruses, adenovirus type 5 (AdV5) and herpes simplex virus type 1 (HSV-1). We further outline the direct and indirect interactions of AAV with those and additional helper viruses.

1 November 2009 in Virus Research
Verified
Journal Article
Closed access
BKBarbara J. Kelly
Barbara J. Kelly
CFCornel Fraefel
Cornel Fraefel
Anthony L. CunninghamAnthony L. Cunningham
Anthony L. Cunningham
RDRussell Diefenbach
Russell Diefenbach

17 May 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMichel Crameri
Michel Crameri
MBMichael Bauer
Michael Bauer
NCNicole Caduff
Nicole Caduff
RWRaphael Walker
Raphael Walker
FSFiona Steiner
Fiona Steiner
JPJovan Pavlovic
Jovan Pavlovic
The type I interferon (IFN) system plays an important role in controlling herpesvirus infections, but it is unclear which IFN-mediated effectors interfere with herpesvirus replication. Here we report that human myxovirus resistance protein B (MxB, also designated Mx2) is a potent human herpesvirus restriction factor in the context of IFN. We demonstrate that ectopic MxB expression restricts a range of herpesviruses from the Alphaherpesvirinae and Gammaherpesvirinae, including herpes simplex virus 1 and 2 (HSV-1 and HSV-2), and Kaposi’s sarcoma-associated herpesvirus (KSHV). MxB restriction of HSV-1 and HSV-2 requires GTPase function, in contrast to restriction of lentiviruses. MxB inhibits the delivery of incoming HSV-1 DNA to the nucleus and the appearance of empty capsids, but not the capsid delivery to the cytoplasm or tegument dissociation from the capsid. Our study identifies MxB as a potent pan-herpesvirus restriction factor which blocks the uncoating of viral DNA from the incoming viral capsid.